Axon Enterprise, Inc. Common Stock Goldman Sachs Communacopia + Technology Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. Good morning, everybody. Welcome to the Axon Fireside Chat at the Goldman Sachs Communacopia + Technology Conference. I have the privilege of introducing Brittany Bagley, who is the Chief Financial Officer and Chief Operating Officer at Axon. My name is Michael Ng, and I cover Axon here at the firm. We have about 35 minutes for today's presentation. First and foremost, thank you so much for being here, Brittany.
Thank you for having me. I always like coming here.
I am thrilled about that. To kick things off, I wanted to ask about Axon's portfolio and key growth drivers. Axon is the market leader in U.S. public safety technology. Historically, Axon has done very well in TASER, body camera, evidence management software. Today, about a third of the software comes from non-evidence software, like 911, Fusus, and the AI Era Plan. How are you thinking about the key growth drivers from here, and what the strategic priority is for the management team?
Yeah. No, it is a great question. It is really nice to be able to share some of those stats with all of you, because these are businesses that we have been talking about and investing behind in the last couple of years. It is great to actually be able to share some of those growth numbers. I think the really important thing to remember about our products, as we have evolved the product portfolio, is that it really is an ecosystem and everything works together. Everything gets better together. As we look towards the future, we are not prioritizing any one product category over another. We continue to be incredibly pleased with how TASER and body cameras are anchoring the portfolio, but then we have added on counter-drone through our Dedrone products. We have added on 911.
We're adding on these other software pieces, and they all just reinforce each other. As we look at our priorities, it's really just to make these products continue to get better, continue to solve problems for our customers, fill in gaps in their ecosystem where we see them, continue to evolve our AI products, because we're only at the very beginning of what AI can do. That's a big area of investment for us. But what we do is we tell you about things well before they actually become meaningful to our P&L. The things that we talk about are things that are the drivers for the next couple of years. Then we start telling you when they become meaningful to our P&L, like some of these software products. But that's the goal is just keep evolving that ecosystem.
Great. Let's talk a little bit about business momentum, bookings, which was a new metric that you complemented in terms of a five-year bookings metric starting last quarter. That number grew over 30% in the second quarter of 2026. Gross bookings grew a little bit more slowly, but could you just talk a little bit about the differences between gross bookings, the new five-year normalized metric? How do you think investors should evaluate this new normalized growth metric alongside your contracted backlog?
Yeah. So we gave the new five-year normalized because we were getting a lot of questions about what role duration of our contracts was playing in bookings. How much of our bookings growth was because we were getting really long-term contracts? We wanted to provide this metric as a way to help all of you look at our five-year normalized bookings. What that really means is that when we look at five-year deals, we take out any of the years that are six and beyond. So you're really just getting a number for five years. Now, if we do a deal that is shorter than five years, we don't gross it up. This is the total bookings that will happen in the next five years.
We thought that would be a helpful metric, both to get to the duration piece, but also as we go forward to help give some comparisons for as we grow our enterprise business. Not all of those deals are going to be five-year deals. Some of our international deals aren't five years. So give everyone a way to look at it. We did it in a quarter where, or a year where it shouldn't make a particularly large difference. We're not expecting there to be a dramatic difference as we look at the year between our normalized bookings and our gross bookings. You could see normalized being higher sometimes. You could see gross being higher sometimes. In Q2, normalized was higher. Gross was lower at 20%. Gross was also comping a 50% growth in bookings from the prior year, so you have to balance some of those things out.
As we look at the year, we really look at both gross and normalized bookings, but we do look a lot at normalized bookings, and we look at our future contracted bookings. We had given the color that we expected our normalized bookings to grow 30%+. We expect our future contracted bookings to grow well above that. You can back into what that means for gross bookings, but it shouldn't have a material difference for the year between gross and normalized.
Great. One common question that I often get from investors is just about Axon's TAM and how penetrated Axon is within its TAM. A couple things that we could tease out here, but maybe just start out, how much does Axon make of a state and local police budget today, and is there opportunity to grow that percentage just in terms of, you know- Yes, absolutely.
I think depending on the department, we're somewhere between 1%-5% of the police budget today. So pick 3% in the middle if you want. I think at some of our largest customers who are buying everything, you get up to that 5%. And those aren't necessarily our numbers. One of the great things about our customers is they publish a lot of this information, so you can go find customers who lay out their budgets and how much Axon is a part of that. So not a huge part of their budget today. Lots of room to continue growing inside of the budget. Police budgets have continued to grow, but we have grown much faster than that, and that is really because we're increasing our share of wallet.
We increase our share of wallet by coming up with products that solve real problems for our customers that they need, that they want to use. Depending on the product, some of them are really mission critical, some of them are life-saving, some of them are about transparency, and as we look at AI, some of them are even more about ROI and actually generating efficiency for the department. So there's different reasons that we're able to do that across our products. But I think we estimate we're about 15% penetrated in our state and local TAM today. And then our overall TAM is about $159 billion-$160 billion from a TAM standpoint. Lots of detail that we can get into all of you on how we get to that TAM. We try to be pretty conservative.
We try to really have it look at only products that we sell today in countries or markets that we can actually apply it. I know there's lots of ways to do TAM. We try and be pretty conservative and think that it just shows that there's a huge opportunity in front of us.
Great. I would've thought that Axon was relatively fully penetrated in TASER, yet last quarter you had your largest individual TASER order in company history. Could you talk a little bit about what's driving this TASER momentum? Is it the TASER 10 refresh? Is it expanded number of seats, if you will?
Yeah. It's different depending on market. The U.S. deal that we were excited to call out last quarter, like our largest ever TASER deal, still happening three-plus years into our refresh cycle. That was an upgrade to TASER 10. So great to see that we still continue to have customers moving to TASER 10. Still a lot of opportunity to do that. We also called out international deals having TASER in them. International has had some real reception to TASER 10. TASER 10 has higher efficacy and more use cases, and so that's really appealing to some of our international customers, and so that's where you're seeing us get into markets that we were not in before.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
